Rigel Pharmaceuticals initiated a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP - immune thrombocytopenic purpura. The focus of these clinical studies is to evaluate the potential of fostamatinib to increase the platelet counts of patients with chronic ITP. Fostamatinib may provide a novel therapeutic for the underlying cause of this autoimmune disease of the blood.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
These proven wealth builders could be exactly what you're searching for right now.
Here's what could happen next to Microsoft shares.
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
It's possible to construct a winning long-term investment strategy with just low-cost index funds.
Since 2021, Dogecoin (DOGE) has consistently been one of the largest cryptocurrencies in the market. The token has attracted tens of billions in investment and is up more than 27,000% since its launch. While the price has fallen considerably since highs, the token has held its own and performed well in 2024. Some do not see the growth stopping anytime soon. According to some analysts, DOGE could reach — and even surpass — the $100 mark. Don't Miss: Dogecoin millionaires are increasing — investor
